Evotec names Joanna Holbrook as CSO: Evotec stock sits 5.39 percent above its low

Published on 10/16/2026 at 10:12 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec expects EUR 465.0 million revenue for the first nine months. Evotec stock costs EUR 2.54 on October 16, 2026, versus the Xetra close.

Leadership and reporting milestones

Evotec appointed Joanna Holbrook on October 15, 2026, effective November 1, 2026.
Preliminary nine-month revenue reached EUR 465.0 million in 2026, while adjusted EBITDA was EUR -42.8 million.
Evotec stock trades at EUR 2.54 at 10:03 a.m. CEST at Lang & Schwarz on October 16, 2026, 0.40 percent above the Xetra close of October 15, 2026.
Evotec will publish its third-quarter and nine-month report on November 5, 2026.

Fotorealistisches Pharma-Labor mit Wissenschaftlern bei Wirkstoffscreening in moderner Biotech-Anlage — Fotorealistisches Pharma-Labor symbolisiert Wirkstoffforschung von Evotec SE, ISIN DE0005664809, moderner Biotech-Standort Hamburg, Illustration mit AI erstellt.

Evotec (ISIN DE0005664809) appointed Dr. Joanna Holbrook as chief scientific officer and a member of its management board on October 15, 2026, effective November 1, 2026, according to EQS News. Evotec stock was trading at EUR 2.54 at Lang & Schwarz on October 16, 2026 at 10:03 a.m. CEST, up 0.40 percent versus the Xetra close of October 15, 2026 at EUR 2.53.

Holbrook brings 25 years of experience

Holbrook will lead Evotec's global scientific strategy across drug discovery, development services, technology platforms and proprietary innovation. The company said she brings more than 25 years of experience in pharmaceutical research, biotechnology and academia, including work at Novo Nordisk, according to EQS News. The appointment gives the recent management transition a defined successor and adds a quantified experience marker to Evotec's scientific strategy.

What does EUR 465.0 million mean?

Evotec expects preliminary revenue of EUR 465.0 million for the first nine months of 2026 and adjusted EBITDA of EUR -42.8 million. The figures were above market expectations, but the company attributed much of the variance to the timing of consensus estimates, according to finanzen.net. Full-year 2026 guidance remains revenue of EUR 570 million to EUR 610 million and adjusted EBITDA of EUR -70 million to EUR -105 million.

Three dated steps shape the story

On September 29, 2026, Evotec announced that chief scientific officer Cord Dohrmann would leave after 16 years, as reported by FinanzNachrichten. On October 13, 2026, Evotec released preliminary nine-month revenue of EUR 465.0 million and adjusted EBITDA of EUR -42.8 million, according to finanzen.net. On October 15, 2026, Holbrook was appointed with effect from November 1, 2026, according to EQS News.

Two dates define the next phase

Holbrook's management-board mandate starts on November 1, 2026, and Evotec is scheduled to publish its third-quarter and nine-month report on November 5, 2026, according to the company's investor-relations calendar. The November report will test whether the preliminary revenue performance translates into a narrower adjusted EBITDA loss.

Stock stays near its yearly low

At EUR 2.54, Evotec stock was EUR 0.13, or 5.39 percent, above its 52-week low of EUR 2.41 as of October 16, 2026. Its market capitalization was EUR 450.7 million on the same date. Evotec's next market test is therefore tied to the November reporting date and the conversion of revenue into operating earnings.

Evotec was trading at EUR 2.54 at Lang & Schwarz on October 16, 2026 at 10:03 a.m. CEST, 0.40 percent above the Xetra close of October 15, 2026 at EUR 2.53. The further course of trading is shown by the continuously updated real-time quote of Evotec stock.